Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Merck KGaA Gives Details On Planned Efficiency Program

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/24/2012 | 05:51pm CEST

-- Germany's Merck provides details about efficiency program.

-- Conglomerate joins a long list of drug makers revamping themselves.

-- Merck KGaA shares fall after restructuring update.

(Adds details, share details, background.)

   By Neetha Mahadevan 
   Of  
 

Pharmaceutical and chemical company Merck KGaA (>> Merck KGaA) said Friday it launched a cost-cutting and efficiency plan in the wake of increased price pressures in the U.S. and Europe and a series of drug development setbacks.

The company said the plan could involve job cuts across all businesses and regions to reduce costs and address "unprecedented market shifts", but it didn't disclose details, saying management still needed to speak with relevant stakeholders for a mutually acceptable solution.

"Over the next two years, Merck needs to address unprecedented market shifts, increasing competition in key product areas and existing inefficiencies in its own organization to ensure the long-term success of its business model," Chief Executive Karl-Ludwig Kley said in a statement.

With its new cost-cutting drive, the German chemical and pharmaceutical company joins a long list of other drug makers who are revamping themselves in response to falling sales and profitability.

The need to cut costs is partly due to mounting pressure stemming from health care reforms in the U.S. and Europe, where governments are increasingly reluctant to reimburse expensive drugs and advocate the use of cheaper generic medicines. Companies such as AstraZeneca Plc (AZ.LN), Novartis AG (NVS), Roche Holding AG (ROG.VX), Pfizer Inc (>> Pfizer Inc.), Eli Lilly & Co (>> Eli Lilly & Co.) have all embarked on cost saving or restructuring programs to keep costs under control.

In addition to set-backs in its drug pipeline, Merck has also been hit by a slowdown in demand at its chemicals division, which led to disappointing developments in the last year and prompted it to tighten its outlook time and again.

In the second-quarter, it recorded a 6.5% drop in revenue at its chemicals division, while in the third-quarter profits fell due largely to weakness in its performance materials division.

The efficiency measures are part of Merck's comprehensive transformation program, announced last year, and comprises two phases, the company said.

In the first two years, Merck plans to set up a new leadership organization, implement efficiency measures and focus on long-term growth, while the second phase will be focused on exploiting new growth opportunities, it added.

Merck KGaA shares fell after the news and at 1545 GMT traded down 1.2% at EUR79.70, while the DAX benchmark index traded 0.6% higher.

-By Neetha Mahadevan, Dow Jones Newswires; +49 69 2972 5507; [email protected]

(Sten Stovall contributed to this article.)

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA 0.22% 5440 Delayed Quote.5.99%
ASTRAZENECA -0.23% 641.4 Delayed Quote.12.58%
ELI LILLY AND COMPANY 0.04% 82.71 Delayed Quote.-2.11%
MERCK KGAA 1.19% 84.7 Delayed Quote.-7.32%
NOVARTIS 0.90% 76.38 Delayed Quote.-6.94%
ROCHE HOLDING LTD. -1.19% 216.4 Delayed Quote.-9.17%
ROCHE HOLDING LTD. -0.97% 186.92 Delayed Quote.-10.49%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
05/23CHROMATOGRAPHY RESIN MARKET TO REGIS : While other players in the global chromat..
AQ
05/22MERCK : Darmstadt, Germany, Ignites Firework of Research Initiatives During its ..
PU
05/22MERCK : Darmstadt, Germany, Survey Reveals Most Thyroid Disorder Patients Find R..
PU
05/17MERCK : Researchers from Merck KGaA Report on Findings in Zika Virus (Mitigating..
AQ
05/17Merck, Pfizer report early data for PD-L1/ALK inhibitor combos
AQ
05/16MERCK : MilliporeSigma to Use Genome Editing in Study of Gut Bacteria to Benefit..
PU
05/15MERCK KGAA : to Host Earnings Call
AQ
05/15MERCK KGAA : to Host Earnings Call
AC
05/15Merck KGaA's Shares Fall After 1Q Results -- Update
DJ
05/15Merck KGaA's 1Q Sales Decline, Dragged by Currency Headwinds
DJ
More news
News from SeekingAlpha
05/23MERCK KG&A (MKGAY) Presents At 2018 UBS Global Healthcare Conference - Slides.. 
05/15Merck's (MKGAF) Management on Q1 2018 Results - Earnings Call Transcript 
05/15Merck KGaA 2018 Q1 - Results - Earnings Call Slides 
05/15Merck KGaA reports Q1 results 
05/02Merck KGaA to develop abituzumab for CRC with SFJ 
Financials (€)
Sales 2018 15 050 M
EBIT 2018 2 940 M
Net income 2018 1 974 M
Debt 2018 7 866 M
Yield 2018 1,51%
P/E ratio 2018 17,80
P/E ratio 2019 17,38
EV / Sales 2018 1,24x
EV / Sales 2019 1,08x
Capitalization 10 818 M
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 96,8 €
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA-7.32%12 665
ABBVIE6.65%163 671
KYOWA HAKKO KIRIN CO LTD2.30%11 958
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD80.22%11 098
JAZZ PHARMACEUTICALS PLC24.09%9 815
CONVATEC GROUP10.02%5 929